Inhalation Sciences signs IRS contract worth 806,000 SEK with returning customer

Inhalation Research Services (IRS) has signed a new contract worth 806,000 SEK with a returning customer for a new in vivo study. ISAB CEO Manoush Masarrat: “Our IRS team and technology deliver world-class precision, performance and partnership – we’re pleased to welcome back this highly-valued client.”

The customer has chosen to use ISAB’s novel intra-tracheal exposure module for this study. The module uses ISAB’s unique “one-animal-at-a-time” precision dosing methodology, where precise, controlled doses of aerosol are administered to a single anaesthetized rodent directly to the lungs (via an intubated incision in the throat) whilst its breathing pattern and aerosol concentrations are carefully monitored. The method delivers exceptionally precise lung absorption and retention data with a typical Standard Deviation of <10%,

Compared to conventional ‘tower testing’ systems - where large groups of rodents in vertical testing systems are simultaneously exposed to the same aerosol dose nasally – intratracheal testing avoids the waste of test substance in the nasal cavity and upper throat and reduces the number of test animals needed (enhancing the ‘3R’ status of the tests.)

ISAB’s IRS department has had a highly productive 2022 with multiple new projects, many with returning clients. ISAB formally launched its Inhalation Research Services in 2019 with the goal of providing efficient, stress-free contract research services to small and mid-range pharmaceutical customers wishing to access ISAB’s inhalation expertise and its exceptionally precise data, without having to purchase new Labtech equipment.

ISAB CEO Manoush Masarrat: “our team and technology deliver world-class precision, performance and partnership – we’re pleased to welcome back this highly-valued client.”

Explore ISAB’s intratracheal testing module here.